Literature DB >> 34250501

Maternal Hyperglycemia Induces Changes in Gene Expression and Morphology in Mouse Placentas.

Molly Eckmann1, Quanhu Sheng2, Scott Baldwin H3, Rolanda L Lister4.   

Abstract

Background: Pregestational diabetes complicates one million pregnancies in the United States and is associated with placental dysfunction. Placental dysfunction can manifest as stillbirth, spontaneous abortions, fetal growth restriction, and preeclampsia in the mother. However, the underlying mechanisms of placental dysfunction are not well understood. Objective: We hypothesize that maternal hyperglycemia disrupts cellular processes important for normal vascular development and function. Study Design: Hyperglycemia, defined as a non-fasting glucose concentration of >250 mg/dL was induced in eight-week-old female CD1 mice by injecting a one-time intraperitoneal dose of 150mg/kg streptozotocin. Control mice received an equal volume of normal saline. Hyperglycemic and control females were mated with CD-1 males. At Embryonic Day 17.5, the pregnant mice were euthanized. Sixty-eight placentas were harvested from the six euglycemic dams and twenty-six placentas were harvested from three hyperglycemic dams. RNA was extracted from homogenized placental tissue (N=12/group; 2-4 placentas per litter of each group). Total RNA was prepared and sequenced. Differentially expressed genes that were >2-fold change was considered significant. Placentas (9-20/group) were fixed in paraffin wax and sectioned at 6 μm. Cross-sectional areas of placental zones were evaluated using slides stained for hematoxylin and eosin, glycogen, collagen, proliferation and apoptosis. Quantification of staining intensity and percent positive nuclei was done using Leica Image Hub Data software. Data were compared between the control and experimental group using t-tests. Values of p < 0.05 were considered to be statistically significant.
Results: The average maternal blood glucose concentrations for control and diabetic dams were 112+/-24 and 473+/-47 respectively (p<0.0001). A higher rate of resorptions was noted in the hyperglycemia exposed placentas compared to euglycemic exposed placentas (24% vs 7%; p=0.04). A total of 24 RNA libraries (12/group) were prepared. Placentas from hyperglycemic pregnancies exhibited 1374 differentially expressed genes (DEGs). The 10 most significantly differentially expressed genes are Filip 1, Prom 2, Fam 78a, Pde4d, Pou3f1, Kcnk5, Dusp4, Cxcr4, Slc6a4 and D430019H16Rik. Their corresponding biologic functions are related to chemotaxis, ossification, cellular and vascular development. Histologically, we found that hyperglycemia exposed placentas demonstrated increased proliferation, apoptosis, and glycogen content and decreased collagen deposition.
Conclusion: There was a higher rate of resorptions in the pregnancies of hyperglycemic dams. Pregestational diabetes resulted in significant changes in placental morphology, including increased glycogen content in the spongiotrophoblast, decreased collagen deposition, increased apoptosis and proliferation in the junction zone. Maternal diabetes causes widespread disruption in multiple cellular processes important for normal vascular development and sets the platform for placenta dysfunction.

Entities:  

Keywords:  Apoptosis; Collagen staining; Differentially expressed genes; Euglycemia; Genome wide mRNA expression; Hyperglycemia; Maternal diabetes; Placenta dysfunction; Proliferation; Streptozotocin; Vascular dysfunction

Year:  2021        PMID: 34250501      PMCID: PMC8270392     

Source DB:  PubMed          Journal:  Gynecol Reprod Health        ISSN: 2639-9342


  31 in total

1.  Characterization of neuritin as a novel angiogenic factor.

Authors:  Dingding Han; Bo Qin; Guoqing Liu; Tingting Liu; Guoqing Ji; Yanhua Wu; Long Yu
Journal:  Biochem Biophys Res Commun       Date:  2011-10-31       Impact factor: 3.575

2.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features.

Authors:  Yang Liao; Gordon K Smyth; Wei Shi
Journal:  Bioinformatics       Date:  2013-11-13       Impact factor: 6.937

3.  Circulatory and renal consequences of pregnancy in diabetic NOD mice.

Authors:  S D Burke; V F Barrette; S David; E V Khankin; M A Adams; B A Croy
Journal:  Placenta       Date:  2011-10-19       Impact factor: 3.481

4.  Pregnancy outcomes in type 2 diabetic patients as compared with type 1 diabetic patients and nondiabetic controls.

Authors:  Kristin M Knight; Loralei L Thornburg; Eva K Pressman
Journal:  J Reprod Med       Date:  2012 Sep-Oct       Impact factor: 0.142

Review 5.  Experimental diabetes induced by alloxan and streptozotocin: The current state of the art.

Authors:  Miroslav Radenković; Marko Stojanović; Milica Prostran
Journal:  J Pharmacol Toxicol Methods       Date:  2015-11-17       Impact factor: 1.950

6.  Influence of murine maternal diabetes on placental morphology, gene expression, and function.

Authors:  Yang Yu; Umashankar Singh; Wei Shi; Toshihiro Konno; Michael J Soares; Rudolf Geyer; Reinald Fundele
Journal:  Arch Physiol Biochem       Date:  2008-04       Impact factor: 4.076

7.  Phosphodiesterase 4 inhibition synergizes with relaxin signaling to promote decidualization of human endometrial stromal cells.

Authors:  Olaf Bartsch; Bettina Bartlick; Richard Ivell
Journal:  J Clin Endocrinol Metab       Date:  2004-01       Impact factor: 5.958

8.  Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands.

Authors:  Inge M Evers; Harold W de Valk; Gerard H A Visser
Journal:  BMJ       Date:  2004-04-05

Review 9.  Mechanisms of early placental development in mouse and humans.

Authors:  Myriam Hemberger; Courtney W Hanna; Wendy Dean
Journal:  Nat Rev Genet       Date:  2019-09-18       Impact factor: 53.242

10.  Obstetric and perinatal outcomes in pregnancies complicated by diabetes, and control pregnancies, in Kronoberg, Sweden.

Authors:  Anna Stogianni; Lena Lendahls; Mona Landin-Olsson; Maria Thunander
Journal:  BMC Pregnancy Childbirth       Date:  2019-05-07       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.